Literature DB >> 27440823

Preventing Diabetes: Early Versus Late Preventive Interventions.

Jaakko Tuomilehto1, Peter E H Schwarz2.   

Abstract

There are a number of arguments in support of early measures for the prevention of type 2 diabetes (T2D), as well as for concepts and strategies at later intervention stages. Diabetes prevention is achievable when implemented in a sustainable manner. Sustainability within a T2D prevention program is more important than the actual point in time or disease process at which prevention activities may start. The quality of intervention, as well as its intensity, should vary with the degree of the identified T2D risk. Nevertheless, preventive interventions should start as early as possible in order to allow a wide variety of relatively low- and moderate-intensity programs. The later the disease risk is identified, the more intensive the intervention should be. Public health interventions for diabetes prevention represent an optimal model for early intervention. Late interventions will be targeted at people who already have significant pathophysiological derangements that can be considered steps leading to the development of T2D. These derangements may be difficult to reverse, but the worsening of dysglycemia may be halted, and thus the clinical onset of T2D can be delayed.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Year:  2016        PMID: 27440823     DOI: 10.2337/dcS15-3000

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  7 in total

1.  Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.

Authors:  Dongzhe Hong; Lei Si; Minghuan Jiang; Hui Shao; Wai-Kit Ming; Yingnan Zhao; Yan Li; Lizheng Shi
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

2.  The association of depression and diabetes across methods, measures, and study contexts.

Authors:  Jaimie C Hunter; Brenda M DeVellis; Joanne M Jordan; M Sue Kirkman; Laura A Linnan; Christine Rini; Edwin B Fisher
Journal:  Clin Diabetes Endocrinol       Date:  2018-01-04

3.  Implementation findings from a hybrid III implementation-effectiveness trial of the Diabetes Prevention Program (DPP) in the Veterans Health Administration (VHA).

Authors:  Laura J Damschroder; Caitlin M Reardon; Mona AuYoung; Tannaz Moin; Santanu K Datta; Jordan B Sparks; Matthew L Maciejewski; Nanette I Steinle; Jane E Weinreb; Maria Hughes; Lillian F Pinault; Xinran M Xiang; Charles Billington; Caroline R Richardson
Journal:  Implement Sci       Date:  2017-07-26       Impact factor: 7.327

4.  Cardiovascular Risk Factors and Provision of Lifestyle Counseling for Diabetes or Prediabetes With Comorbid Obesity: Analysis of Office-Based Physician Visits Made by Patients 20 Years of Age or Older.

Authors:  Samantha Karr; Rebekah M Jackowski; Kelsey D Buckley; Kathleen A Fairman; David A Sclar
Journal:  Diabetes Spectr       Date:  2019-02

5.  Construct validity of the Suboptimal Health Status Questionnaire-25 in a Ghanaian population.

Authors:  Eric Adua; Ebenezer Afrifa-Yamoah; Kwasi Frimpong; Esther Adama; Shantha P Karthigesu; Enoch Odame Anto; Emmanuel Aboagye; Yuxiang Yan; Youxin Wang; Xuerui Tan; Wei Wang
Journal:  Health Qual Life Outcomes       Date:  2021-07-19       Impact factor: 3.186

6.  Evaluation of Two-Diabetes Related microRNAs Suitability as Earlier Blood Biomarkers for Detecting Prediabetes and type 2 Diabetes Mellitus.

Authors:  Haifa Abdullah Al-Muhtaresh; Ghada Al-Kafaji
Journal:  J Clin Med       Date:  2018-01-26       Impact factor: 4.241

Review 7.  Intimate Partner Violence: A Risk Factor for Gestational Diabetes.

Authors:  Carmen Pheiffer; Stephanie Dias; Sumaiya Adam
Journal:  Int J Environ Res Public Health       Date:  2020-10-26       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.